Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reactions Weekly
Published in: Reactions Weekly 1/2012

01-03-2012 | Case report

Chorionic gonadotropin/follitropin-α

Ovarian hyperstimulation syndrome: case report

Published in: Reactions Weekly | Issue 1/2012

Login to get access

Excerpt

An event is serious (FDA MedWatch definition) when the patient outcome is:
  • death
  • life-threatening
  • hospitalisation
  • disability
  • congenital anomaly
  • requires intervention to prevent permanent impairment or damage
…
Literature
1.
Chen PH, Hsien-Liu, Lee SL, Chang CY, Chang CC.Ovarian hyperstimulation syndrome associated with von Willebrand’s disease. Taiwanese Journal of Obstetrics and Gynecology 50: 217-9, No. 2, Jun 2011 - Taiwan
Metadata
Title
Chorionic gonadotropin/follitropin-α
Ovarian hyperstimulation syndrome: case report
Publication date
01-03-2012
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2012
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.2165/00128415-201213920-00043

Other articles of this Issue 1/2012

Reactions Weekly 1/2012 Go to the issue

Case report

Trastuzumab

Case report

Busulfan

Case report

Bevacizumab

Case report

Lidocaine

Case report

Ademetionine

Case report

Antineoplastics